Recombinant Human Insulin-induced gene 1 protein (INSIG1)

What is the functional role of INSIG1 in sterol regulatory pathways?

INSIG1 serves as a crucial regulatory element in sterol metabolism through two primary mechanisms. First, it binds to sterol regulatory element-binding protein cleavage-activating protein (SCAP) in the endoplasmic reticulum, effectively preventing the proteolytic processing required for sterol regulatory element-binding protein (SREBP) activation . This interaction prevents SREBP from being transported to the Golgi for processing into its active transcription factor form, thus blocking SREBP-mediated gene transcription . Second, INSIG1 mediates the sterol-accelerated proteolytic degradation of HMG-CoA reductase (HMGCR), directly impacting the mevalonate pathway . This dual function establishes INSIG1 as a central negative feedback regulator that acts as a "brake" on lipogenic pathways in various tissues, particularly in adipocytes and hepatocytes .

Methodologically, researchers investigating these pathways typically employ cell culture models with INSIG1 overexpression or knockdown, followed by western blot analysis to track changes in SREBP processing and target gene expression. Transcriptome analysis after INSIG1 manipulation provides comprehensive insights into its regulatory networks.

How does INSIG1 expression change during metabolic disease progression?

INSIG1 exhibits dynamic expression patterns that correlate with metabolic disease states. In normal mice developing diet-induced obesity, INSIG1 mRNA increases progressively in adipose tissue as obesity develops and declines during dietary restriction . This pattern suggests INSIG1 responds to nutritional status and may serve as a compensatory mechanism to limit excessive lipogenesis during caloric excess.

In cell culture models, INSIG1 and INSIG2 expression rises in parallel with adipocyte protein 2 (aP2) mRNA during the differentiation of 3T3-L1 preadipocytes . Notably, carbohydrate response element-binding protein (ChREBP) mRNA, a lipogenic transcription factor, becomes detectable only during differentiation and specifically in high glucose (25 mM) conditions but not in low glucose (5 mM) environments .

Researchers commonly track these expression changes using quantitative PCR for mRNA levels and western blot analysis for protein levels across different metabolic conditions and disease stages.

What experimental models are most effective for studying INSIG1 function?

Several experimental systems have proven valuable for investigating INSIG1 biology:

When studying INSIG1 function in adipocyte differentiation, researchers frequently employ transfection of mouse or human INSIG1 into 3T3-L1 preadipocytes followed by Oil Red O staining to assess lipid accumulation and western blot analysis to measure adipogenic markers (aP2, PPARγ2) . For INSIG1 function in virus production, pseudovirus production assays with protein overexpression or gene knockouts in 293T cells provide valuable insights .

How does INSIG1 coordinate with different E3 ubiquitin ligases to regulate protein degradation pathways?

This substrate-specific coordination suggests INSIG1 may serve as an adaptor protein that recruits different E3 ligases based on the cellular context and targeted substrate. Research methods to investigate these interactions include:

• Co-immunoprecipitation assays to confirm physical interactions between INSIG1 and specific E3 ligases

• Ubiquitination assays using inhibitors specific to proteasomal or lysosomal degradation pathways

• Microscopy to track intracellular localization of INSIG1, target proteins, and degradation machinery components at membrane sites such as the endoplasmic reticulum and endosomes

These methodological approaches have revealed that INSIG1 functions as a sentinel responsive to HIV-1 production, inhibiting HIV-1 replication specifically by accelerating the degradation of Gag protein .

What are the metabolic consequences of INSIG1 deficiency in different tissues during disease progression?

INSIG1 deficiency produces tissue-specific and context-dependent effects that reveal its complex role in metabolic homeostasis. In liver tissue, INSIG1 knockout (KO) mice show a fascinating metabolic paradox: despite increased SREBP activity and hepatic lipid deposition, they display protection from non-alcoholic steatohepatitis (NASH) when fed a NASH-inducing diet .

This protection stems from multiple mechanisms:

• Enhanced desaturase activity and lipid remodeling that prevents hepatic lipotoxicity

• Decreased liver infiltration of inflammatory cells (CD3+ T cells and CD45R+ B cells)

• Reduced extracellular matrix deposition

• Suppression of pathways involved in ER stress (e.g., Ddit3), oxidative damage, and apoptosis (e.g., Bax and Fasl)

Interestingly, INSIG1 KO mice are smaller/shorter than their wild-type littermates but do not show differences in fat mass, liver weight to body weight ratio, or markers of systemic and peripheral insulin resistance .

The research methodologies for investigating these phenotypes include:

• Immunohistochemistry to assess inflammatory cell infiltration

• Picrosirius red staining to evaluate extracellular matrix deposition

• Transcriptome analysis with Ingenuity Pathway Analysis (IPA) to identify affected molecular pathways

• Metabolic profiling to measure glucose, triglycerides, cholesterol, and free fatty acids

These findings suggest that targeted manipulation of INSIG1 activity could potentially provide therapeutic benefits in specific metabolic disease contexts.

How can researchers effectively measure and interpret INSIG1-mediated effects on SREBP processing in different experimental systems?

Measuring INSIG1-mediated effects on SREBP processing requires careful experimental design and interpretation due to the multi-step nature of SREBP activation. Researchers should implement a comprehensive strategy:

• Protein processing analysis: Western blot analysis should track both precursor (inactive) and cleaved (nuclear, active) forms of SREBP1 and SREBP2 to assess processing efficiency. When INSIG1 is overexpressed, researchers can observe decreased levels of cleaved SREBP forms .

• Target gene expression: qRT-PCR to measure mRNA levels of SREBP target genes (e.g., fatty acid synthase, HMG-CoA synthase) provides functional readouts of SREBP transcriptional activity.

• Subcellular fractionation: Separating nuclear and cytoplasmic/membrane fractions allows direct measurement of SREBP nuclear translocation.

• Confocal microscopy: Immunofluorescence staining of SREBP to visualize its subcellular localization provides spatial information about processing status.

• Control for sterol levels: Since sterol levels affect INSIG1-SCAP interactions, researchers must carefully control or measure cellular sterol content to avoid confounding results. Importantly, during HIV-1 production, the cholesterol content of cells does not change significantly, suggesting INSIG1 can regulate protein degradation through cholesterol-independent mechanisms .

• Time-course experiments: SREBP processing dynamics change over time, particularly after stimuli like insulin treatment or viral infection, necessitating temporal analysis.

When comparing data across different experimental systems, researchers should consider cell type-specific differences in the INSIG1-SREBP regulatory axis. For instance, adipocytes and hepatocytes may exhibit different baseline INSIG1 expression levels and responsiveness to metabolic stimuli.

What is the role of INSIG1 in viral infection and how does it differ from its metabolic functions?

INSIG1 plays a surprising role in viral infection that appears mechanistically distinct from its metabolic functions. During HIV-1 infection, INSIG1 is upregulated specifically during virus production but not during the infection process, suggesting it functions inside cells rather than at the plasma membrane .

Key findings about INSIG1's antiviral activity include:

• Inhibition mechanism: INSIG1 inhibits HIV-1 production by accelerating the degradation of HIV-1 Gag protein, a critical structural component required for viral assembly .

• Degradation pathway: Unlike INSIG1-mediated HMGCR degradation (which occurs via AMFR and the proteasome), INSIG1 promotes Gag degradation by coordinating with TRC8 E3 ligase through the lysosome pathway .

• Experimental evidence:

  • Overexpression of INSIG1 significantly inhibits HIV-1 production in both 293T and Jurkat cells for both Env and VSV-G enveloped pseudoviruses

  • INSIG1 overexpression reduces cellular levels of Pr55 Gag protein but does not affect viral glycoproteins (Env and VSV-G)

  • Knockout of INSIG1 using CRISPR/Cas9 increases HIV-1 production and is associated with Gag protein accumulation

  • Reintroducing INSIG1 with a native promoter in knockout cells restores HIV-1 production to wild-type levels

This antiviral function represents a cholesterol-independent role for INSIG1 through the INSIG1-TRC8 E3 ligase system, highlighting its multifunctionality beyond metabolic regulation. Researchers studying these distinct functions should carefully consider the cellular context and implement appropriate controls for each pathway.

How do genetic variants of INSIG1 affect its function in experimental models and clinical contexts?

While the search results don't specifically address INSIG1 genetic variants, researchers interested in this area should consider the following methodological approaches:

• Functional characterization of variants: Recombinant expression of INSIG1 variants in appropriate cell models (hepatocytes, adipocytes) followed by assessment of:

  • Binding affinity to key partners (SCAP, TRC8, AMFR)

  • Protein stability and half-life measurements

  • Subcellular localization

  • Effect on SREBP processing and target gene expression

• Disease association studies: Analysis of INSIG1 variants in cohorts with metabolic disorders (obesity, NAFLD/NASH, dyslipidemia) or relevant viral infections to identify potential associations with disease susceptibility or progression.

• Animal models: Generation of knock-in mice expressing specific INSIG1 variants to assess phenotypic consequences in vivo, particularly in response to high-fat diet challenges or viral infections.

• Structure-function analysis: Understanding how specific variants affect protein structure and interaction domains. This may require crystallography or modeling approaches since the three-dimensional structure of INSIG1 has been challenging to resolve due to its multiple transmembrane domains.

• Expression quantitative trait loci (eQTL) analysis: Evaluation of how variants affect INSIG1 expression levels in different tissues and conditions.

When conducting such studies, researchers should carefully document the specific variant nomenclature according to standard guidelines and consider both common and rare variants in their analysis.

What are the most effective approaches for generating and validating INSIG1 knockout models?

Creating reliable INSIG1 knockout models requires careful consideration of the experimental system and validation approach:

• CRISPR/Cas9 gene editing: The most common contemporary approach for generating INSIG1 knockout cell lines, as demonstrated in the literature where CRISPR/Cas9 was used to create INSIG1 knockout 293T cells . Key considerations include:

  • Guide RNA design targeting early exons to ensure complete protein disruption

  • Screening multiple clones to identify complete knockouts

  • Sequencing validation of the targeted region

• Validation strategies: Comprehensive validation of INSIG1 knockout models should include:

  • Western blot analysis to confirm absence of INSIG1 protein

  • qRT-PCR to verify reduction in INSIG1 mRNA

  • Functional assays showing expected downstream effects (increased SREBP processing, enhanced HIV-1 production)

  • Rescue experiments by reintroducing INSIG1 with native promoter and synonymous encoding sequence to restore wild-type phenotype

• Control for compensation: Potential compensatory upregulation of INSIG2 should be assessed, as these proteins have partially overlapping functions. Researchers should measure INSIG2 levels in INSIG1 knockout models.

• Tissue-specific approaches: For in vivo studies, conditional knockout strategies using Cre-loxP systems targeting specific tissues (liver, adipose) may be preferable to global knockouts, which could have developmental consequences.

The phenotypic analysis of INSIG1 knockout models should include assessment of relevant pathways through both targeted and unbiased approaches, such as transcriptome analysis, to identify affected molecular networks and unexpected compensatory mechanisms .

What technical considerations are important when measuring INSIG1 protein interactions and degradation pathways?

Investigating INSIG1 protein interactions and degradation pathways presents several technical challenges that researchers should address:

• Membrane protein considerations: As INSIG1 is a membrane-bound protein with multiple transmembrane domains, standard interaction assays may require modification:

  • Use of mild detergents for extraction that maintain protein-protein interactions

  • Split-ubiquitin or membrane yeast two-hybrid systems for interaction screening

  • Proximity labeling approaches (BioID, APEX) to identify interactions in native cellular environments

• Degradation pathway determination: When studying INSIG1-mediated protein degradation, researchers should distinguish between proteasomal and lysosomal pathways:

  • Use specific inhibitors: MG132 for proteasome, chloroquine or bafilomycin A1 for lysosome

  • Monitor ubiquitination patterns (K48 linkage suggests proteasomal degradation, while K63 may indicate lysosomal targeting)

  • Track protein half-life in the presence of different inhibitors

• Co-localization analysis: Since INSIG1 functions at intracellular membrane sites such as the endoplasmic reticulum and endosomes, co-localization studies with compartment markers are essential :

  • Confocal microscopy with appropriate markers for ER, Golgi, and endosomes

  • Super-resolution microscopy for detailed spatial relationships

  • Live-cell imaging to track dynamic interactions

• Specificity controls: When studying E3 ligase interactions (AMFR, TRC8), researchers should:

  • Use inactive E3 ligase mutants as negative controls

  • Perform siRNA/shRNA knockdown of specific E3 ligases to confirm pathway specificity

  • Include immunoprecipitation controls to exclude non-specific binding

• Sterol dependence assessment: Since INSIG1 function can be sterol-dependent or independent, researchers should:

  • Control cellular sterol content using lipoprotein-depleted media

  • Use sterol depletion/repletion experiments to differentiate sterol-dependent and independent functions

  • Measure cellular cholesterol content alongside functional assays to correlate with observed effects

These technical considerations ensure accurate characterization of INSIG1's diverse functions in protein degradation pathways.

How might INSIG1-targeted therapeutics be developed for metabolic diseases or viral infections?

The multifunctional nature of INSIG1 presents intriguing therapeutic possibilities for both metabolic diseases and viral infections, though with important considerations:

For metabolic disease applications:

• INSIG1 activation could theoretically reduce excessive lipogenesis in conditions like NAFLD by enhancing its "brake" function on SREBP processing .

• Paradoxically, INSIG1 inhibition might be beneficial in some contexts, as INSIG1 knockout mice show protection from NASH through enhanced lipid remodeling and reduced inflammation despite increased hepatic lipid content .

For antiviral applications:

• Enhancing INSIG1 expression or activity could potentially boost its HIV-1 inhibitory effects by accelerating Gag protein degradation .

• Interventions targeting the INSIG1-TRC8 interaction specifically might enhance viral protein degradation without affecting metabolic pathways.

Development approaches should include:

• Structure-based drug design: Though challenging due to INSIG1's transmembrane nature, focusing on specific protein-protein interaction domains.

• Pathway modulators: Compounds that indirectly enhance INSIG1 expression or activity through upstream regulatory pathways.

• Tissue-specific delivery: Technologies that target liver or immune cells specifically to minimize off-target effects.

• Screening strategies: High-throughput assays measuring INSIG1-mediated protein degradation, SREBP processing, or viral production.

Researchers must carefully consider potential side effects given INSIG1's role in fundamental metabolic processes and design therapeutic strategies that modulate specific INSIG1 functions while minimizing disruption to other pathways.

How does INSIG1 function change in different cell types and what are the implications for tissue-specific research?

INSIG1 exhibits notable cell type-specific functions that researchers must consider when designing and interpreting experiments:

In adipocytes:

• INSIG1 expression rises during differentiation of preadipocytes, paralleling aP2 mRNA .

• Overexpression completely prevents differentiation and lipid accumulation in 3T3-L1 preadipocytes .

• INSIG1 blocks upregulation of adipogenic transcription factors PPARγ2 and ChREBP while reducing downregulation of preadipocyte factor 1 .

In hepatocytes:

• INSIG1 deficiency leads to increased lipid deposition but paradoxically protects from NASH through enhanced lipid remodeling and reduced inflammation .

• INSIG1 knockout mice show decreased liver infiltration of lymphocytes and reduced ECM deposition despite the model being only mildly NASH-inducing .

In immune cells:

• INSIG1 is upregulated during HIV-1 production in T-cell lines .

• INSIG1 coordinates with TRC8 to promote lysosomal degradation of viral Gag protein .

These tissue-specific functions suggest several methodological implications:

Understanding these tissue-specific differences is critical for translating basic INSIG1 research into targeted therapeutic approaches for metabolic diseases or viral infections.

What is known about the evolutionary conservation of INSIG1 and how can comparative biology inform human INSIG1 research?

Though not explicitly covered in the search results, evolutionary conservation analysis of INSIG1 represents an important research direction that can provide insights into functional domains and species-specific adaptations. Researchers investigating this area should consider:

• Sequence conservation analysis: Comparing INSIG1 sequences across species to identify highly conserved regions likely representing functional domains critical for:

  • SCAP binding and SREBP regulation

  • E3 ligase interactions (AMFR, TRC8)

  • Transmembrane topology and ER localization

• Functional conservation testing: Experimental approaches to determine whether INSIG1 from different species can complement human INSIG1 functions:

  • Cross-species rescue experiments in knockout models

  • Chimeric protein studies to map functional domains

  • Heterologous expression systems to test conservation of interaction partners

• Adaptive evolution analysis: Identifying regions under positive selection that might reflect species-specific adaptations related to:

  • Metabolic adaptations to different diets

  • Resistance to pathogens (especially for antiviral functions)

  • Tissue-specific expression patterns

• Model organism selection: Choosing appropriate model organisms for studying specific INSIG1 functions based on:

  • Conservation of regulatory pathways

  • Similarity of metabolic physiology

  • Susceptibility to relevant pathogens

Comparative biology approaches can help researchers prioritize functional domains for detailed study and may identify novel INSIG1 functions that have evolved in specific lineages, potentially revealing new therapeutic targets or experimental approaches.